Settlement: $280M Settlement Reached in Celgene Off-Label Cancer Drugs Lawsuit

Santa Clara, CA: Celgene has agreed to pay $280 million to settle allegations made by a California Whistleblower under the False Claims Act that the biotech company promoted off-label uses for two of its cancer drugs. [Original Article]